Evaluation of the effect of α-defensin human neutrophil peptides on neutrophil apoptosis

International Journal of Molecular Medicine

Volumn 26, Issue 6, 2010, Pages 925-934

  Nagaoka, Isao ^a   Suzuki, Kaori ^a   Murakami, Taisuke ^a   Niyonsaba, François ^a   Tamura, Hiroshi ^b   Hirata, Michimasa ^c  

^a JUNTENDO UNIVERSITY   (Japan)

^b Seikagaku Biobusiness Corporation   (Japan)

^c Ohtaka Enzyme Co Ltd   (Japan)

Author keywords

Antimicrobial peptides; Apoptosis; Defensins; Innate immunity; Neutrophils

Indexed keywords

ALPHA DEFENSIN; ANTIINFECTIVE AGENT; CASPASE 3; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; PROTEIN BCL XL; PURINERGIC P2Y6 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TRUNCATED HEMOGLOBIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

EID: 78649970956     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000544     Document Type: Article

References (60)

1. Smith JA: Neutrophils, host defense, and inflammation: a double-edged swords. J Leukoc Biol 56: 672-686, 1994.
2. Whyte M, Renshaw S, Lawson R and Bingle C: Apoptosis and the regulation of neutrophil lifespan. Biochem Soc Trans 27: 802-807, 1999.
3. Akgul C, Moulding DA and Edwards SW: Molecular control of neutrophil apoptosis. FEBS Lett 487: 318-322, 2001.
4. Simon HU: Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev 193: 101-110, 2003.
5. Colotta F, Re F, Polentarutti N, Sozzani S and Mantovani A: Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80: 2012-2020, 1992.
6. Jimenez MF, Watson RWG, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, and Marshall JC: Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 132: 1263-1220, 1997.
7. Keel M, Ungethüm U, Steckholzer U, Niedere E, Hartung T, Trentz O and Ertel W: Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 90: 3356-3363, 1997.
8. Matute-Bello G, Liles WC, Radella F II, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD and Martin TR: Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 156: 1969-1977, 1997.
9. Oberholzer C, Oberholzer A, Clare-Salzler M and Moldawer LL: Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J 15: 879-892, 2001.
10. Cohen J: The immunopathogenesis of sepsis. Nature 420: 885-891, 2002.
11. Liles WC, Kiener PA, Ledbetter JA, Aruffo A and Klebanoff SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 184: 429-440, 1996.
12. Kasahara Y, Iwai K, Yachie A, Ohta K, Konno A, Seki H, Miyawaki T and Taniguchi N: Involvement of reactive oxygen intermiediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89: 1748-1753, 1997.
13. Gamberale R, Giordano M, Trevani AS, Andonegui G and Geffner JR: Modulation of human neutrophil apoptosis by immune complexes. J Immunol 161: 3666-3674, 1998.
14. Allen L, Dockrell DH, Pattery T, Lee DG, Cornelis P, Hellewell PG and Whyte MKB: Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J Immunol 174: 3643-3649, 2005.
15. Hancock REW and Diamond G: The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8: 402-410, 2000.
16. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3: 710-720, 2003.
17. Selsted ME and Ouellette AJ: Mammalian defensins in the antimicrobial immune response. Nat Immunol 6: 551-557, 2005.
18. Gennaro R and Zanetti M: Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 55: 31-49, 2000.
19. Niyonsaba F, Nagaoka I and Ogawa H: Human defensins and cathelicidins in the skin: beyond direct antimicrobial properties. Crit Rev Immunol 26: 545-575, 2006.
20. Rehaume LM and Hancock REW: Neutrophil-erived defensins as modulators of innate immune function. Crit Rev Immunol 28: 185-200, 2006.
21. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J and Wright SC: Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 63: 1291-1297, 1995.
22. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B and Salcedo R: The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 238: 325-332, 1996. (Pubitemid 26188246)
23. Yang D, Chertov O and Oppenheim JJ: Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 69: 691-697, 2001. (Pubitemid 32466405)
24. Yang D, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ and Chertov O: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069-1074, 2000.
25. Niyonsaba F, Ogawa H and Nagaoka I: Human β-defensin-2 functions as a chemotactic agent for tumor necrosis factor-α-treated human neutrophils. Immunology 111: 273-281, 2004. (Pubitemid 38365749)
26. 7. J Immunol 176: 3044-3052, 2006.
27. Nagaoka I, Niyonsaba F, Tsutsumi-Ishii Y, Tamura H and Hirata M: Evaluation of the effect of human β-defensins on neutrophil apoptosis. Int Immunol 20: 543-553, 2008. (Pubitemid 351436191)
28. 6 signaling pathway. Blood 107: 2936-2942, 2006.
29. Jin J, Dasari R, Sistare FD and Kunapuli SP: Distribution of P2Y receptor subtypes on hematopoietic cells. Br J Pharmacol 123: 789-794, 1998. (Pubitemid 28085377)
30. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA and Weisman GA: International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341, 2006.
31. Mamedova LK, Joshi BV, Gao ZG, von Kügelgen I and Jacobson KA: Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol 67: 1763-1770, 2004.
32. Majewska E, Sulowska Z and Baj Z: Spontaneous apoptosis of neutrophils in whole blood and its relation to apoptosis gene proteins. Scand J Immunol 52: 496-501, 2000.
33. Cossarizza A, Baccarani-Contri M, Kalashnikova G and Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197: 40-45, 1993.
34. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
35. Nagaoka I, Yomogida S, Tamura H and Hirata M: Antibacterial cathelicidin peptide CAP11 inhibits the lipopolysaccharide (LPS)-induced suppression of neutrophil apoptosis by blocking the binding of LPS to target cells. Inflamm Res 53: 609-622, 2004.
36. Biffl WL, Moore EE, Moore FA, Barnett CC Jr, Carl VS and Peterson VM: Interleukin-6 delays neutrophil apoptosis. Arch Surg 131: 24-30, 1996.
37. Territo MC, Ganz T, Selsted ME and Lehrer R: Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 84: 2017-2020, 1989.
38. Yang D, Chen Q, Chertov O and Oppenheim JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 68: 9-14, 2000.
39. Lillard JW Jr, Boyaka PN, Chertov O, Oppenheim JJ and McGhee JR: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci USA 96: 651-656, 1999.
40. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998. (Pubitemid 28391865)
41. Lamothe B and Aggarwal BB: Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 22: 269-279, 2002.
42. 4 nucleotide receptors. Biochem Pharmacol 65: 923-931, 2003.
43. 6 receptor activation. Pharmacol Res 58: 232-239, 2008.
44. Korcok J, Raimundo LN, Du X, Sims SM and Dixon SJ: P2Y6 nucleotide receptors activate NF-κB and increase survival of osteoclasts. J Biol Chem 280: 16909-16915, 2005. (Pubitemid 41389150)
45. Jiang Y, Borrelli L, Bacskai BJ, Kanaoka Y and Boyce JA: P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells. J Immunol 182: 1129-1137, 2009.
46. Matsuzaki K: Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1462: 1-10, 1999.
47. 7 receptor activator, the human cathelicidin-derived peptide LL-37, induces IL-1β processing and release. J Immunol 172: 4987-4994, 2004.
48. Barlow PG, Li Y, Wilkinson TS, Bowdish DME, Lau YE, Cosseau C, Haslett C, Simpson AJ, Hancock RE and Davidson DJ: The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol 80: 509-520, 2006.
49. Gudmundsson GH and Agerberth B: Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods 232: 45-54, 1999.
50. Bowdish DM, Davidson DJ and Hancock RE: A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 6: 35-51, 2005. (Pubitemid 40259800)
51. Chen CI, Schaller-Bals S, Paul KP, Wahn U and Bals R: β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 3: 45-50, 2004. (Pubitemid 38397023)
52. Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A and Ganz T: Determinants of Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 8: 1064-1069, 2001.
53. Ganz T: Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 55: 568-571, 1987.
54. Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS and Borregaard N: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951-3959, 2001.
55. Theilgaard-Mönch K, Knudsen S, Follin P and Borregaard N: The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol 172: 7684-7693, 2004.
56. Zychlinsky A and Sansonetti P: Apoptosis in bacterial pathogenesis. J Clin Invest 100: 493-496, 1997.
57. Liu CY, Lin HC, Yu CT, Lin SM, Lee KY, Chen HC, Chou CL, Huang CD, Chou PC, Liu WT, Wang CH and Kuo HP: The concentration-dependent chemokine release and pro-apoptotic effects of neutrophil-derived alpha-defensin-1 on human bronchial and alveolar epithelial cells. Life Sci 80: 749-758, 2007.
58. Aarbiou J, Tjabringa GS, Verhoosel RM, Ninaber DK, White SR, Peltenburg LT, Rabe KF and Hiemstra PS: Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL-37. Inflamm Res 55: 119-127, 2006.
59. Aarbiou J, Ertmann M, van Wetering S, van Noort P, Rook D, Rabe KF, Litvinov SV, van Krieken JH, de Boer WI and Hiemstra PS: Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J Leukoc Biol 72: 167-174, 2002.
60. Yoshioka S, Mukae H, Ishii H, Kakugawa T, Ishimoto H, Sakamoto N, Fujii T, Urata Y, Kondo T, Kubota H, Nagata K and Kohno S: Alpha-defensin enhances expression of HSP47 and collagen-1 in human lung fibroblasts. Life Sci 80: 1839-1845, 2007.